Siegfried Holding 과거 수익 실적
과거 기준 확인 2/6
Siegfried Holding은 연평균 23%의 비율로 수입이 증가해 온 반면, Life Sciences 산업은 수입이 증가했으며, 연간 12.3%였습니다. 매출은 연평균 11.4%의 비율로 증가했습니다. Siegfried Holding의 자기자본이익률은 14.2%이고 순이익률은 10%입니다.
주요 정보
23.0%
수익 성장률
22.5%
EPS 성장률
| Life Sciences 산업 성장 | 17.6% |
| 매출 성장률 | 11.4% |
| 자기자본 수익률 | 14.2% |
| 순이익 | 10.0% |
| 다음 실적 업데이트 | 18 Feb 2025 |
최근 과거 실적 업데이트
Recent updates
Siegfried Holding AG's (VTX:SFZN) Price In Tune With Earnings
Nov 09
Is Siegfried Holding (VTX:SFZN) Using Too Much Debt?
Sep 12A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Aug 04Siegfried Holding AG (VTX:SFZN) Not Flying Under The Radar
Jun 17Siegfried Holding AG's (VTX:SFZN) CEO Compensation Looks Acceptable To Us And Here's Why
Apr 12Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Mar 15Earnings Miss: Siegfried Holding AG Missed EPS By 18% And Analysts Are Revising Their Forecasts
Feb 23Siegfried Holding AG's (VTX:SFZN) Business Is Yet to Catch Up With Its Share Price
Jan 27Is Siegfried Holding AG (VTX:SFZN) Worth CHF840 Based On Its Intrinsic Value?
Jan 07Is Now The Time To Put Siegfried Holding (VTX:SFZN) On Your Watchlist?
Dec 02We Think Siegfried Holding (VTX:SFZN) Can Stay On Top Of Its Debt
Nov 13A Look At The Intrinsic Value Of Siegfried Holding AG (VTX:SFZN)
Sep 28Here's Why We Think Siegfried Holding (VTX:SFZN) Might Deserve Your Attention Today
Aug 16With EPS Growth And More, Siegfried Holding (VTX:SFZN) Makes An Interesting Case
May 13Is Siegfried Holding (VTX:SFZN) Using Too Much Debt?
Apr 25With EPS Growth And More, Siegfried Holding (VTX:SFZN) Makes An Interesting Case
Jan 20Is Siegfried Holding (VTX:SFZN) A Risky Investment?
Dec 28Here's Why Siegfried Holding (VTX:SFZN) Has Caught The Eye Of Investors
Oct 13Siegfried Holding (VTX:SFZN) Has A Pretty Healthy Balance Sheet
Sep 25Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Jun 24Siegfried Holding (VTX:SFZN) Seems To Use Debt Quite Sensibly
Apr 08Do Siegfried Holding's (VTX:SFZN) Earnings Warrant Your Attention?
Mar 21Does Siegfried Holding (VTX:SFZN) Have A Healthy Balance Sheet?
Dec 23Should You Be Adding Siegfried Holding (VTX:SFZN) To Your Watchlist Today?
Dec 05Here's Why Siegfried Holding (VTX:SFZN) Can Manage Its Debt Responsibly
Sep 19If You Like EPS Growth Then Check Out Siegfried Holding (VTX:SFZN) Before It's Too Late
Sep 01These 4 Measures Indicate That Siegfried Holding (VTX:SFZN) Is Using Debt Reasonably Well
Jun 11Here's Why We Think Siegfried Holding (VTX:SFZN) Is Well Worth Watching
May 25Is Siegfried Holding (VTX:SFZN) A Risky Investment?
Mar 03Shareholders Are Thrilled That The Siegfried Holding (VTX:SFZN) Share Price Increased 227%
Jan 18Do Fundamentals Have Any Role To Play In Driving Siegfried Holding AG's (VTX:SFZN) Stock Up Recently?
Dec 22
What Kind Of Shareholders Hold The Majority In Siegfried Holding AG's (VTX:SFZN) Shares?
Nov 25수익 및 비용 분석
수익 및 비용 분석
Siegfried Holding 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Jun 24 | 1,284 | 129 | 108 | 42 |
| 31 Mar 24 | 1,278 | 121 | 107 | 43 |
| 31 Dec 23 | 1,271 | 113 | 107 | 43 |
| 30 Sep 23 | 1,261 | 131 | 75 | 44 |
| 30 Jun 23 | 1,250 | 149 | 44 | 45 |
| 31 Mar 23 | 1,240 | 153 | 44 | 44 |
| 31 Dec 22 | 1,230 | 156 | 43 | 43 |
| 30 Sep 22 | 1,226 | 143 | 62 | 43 |
| 30 Jun 22 | 1,222 | 129 | 80 | 42 |
| 31 Mar 22 | 1,162 | 112 | 73 | 41 |
| 31 Dec 21 | 1,102 | 96 | 66 | 40 |
| 30 Sep 21 | 1,013 | 83 | 70 | 38 |
| 30 Jun 21 | 924 | 69 | 73 | 36 |
| 31 Mar 21 | 884 | 65 | 70 | 34 |
| 31 Dec 20 | 845 | 61 | 68 | 31 |
| 30 Sep 20 | 836 | 52 | 75 | 29 |
| 30 Jun 20 | 828 | 43 | 83 | 28 |
| 31 Mar 20 | 831 | 48 | 85 | 30 |
| 31 Dec 19 | 834 | 53 | 87 | 33 |
| 30 Sep 19 | 822 | 56 | 72 | 34 |
| 30 Jun 19 | 811 | 58 | 58 | 34 |
| 31 Mar 19 | 803 | 57 | 58 | 31 |
| 31 Dec 18 | 794 | 56 | 58 | 27 |
| 30 Sep 18 | 786 | 52 | 61 | 27 |
| 30 Jun 18 | 779 | 49 | 64 | 26 |
| 31 Mar 18 | 765 | 45 | 61 | 26 |
| 31 Dec 17 | 750 | 41 | 58 | 26 |
| 30 Sep 17 | 732 | 38 | 55 | 25 |
| 30 Jun 17 | 713 | 36 | 52 | 24 |
| 31 Mar 17 | 716 | 32 | 53 | 23 |
| 31 Dec 16 | 718 | 28 | 54 | 21 |
| 30 Sep 16 | 676 | 30 | 53 | 22 |
| 30 Jun 16 | 633 | 33 | 51 | 23 |
| 31 Mar 16 | 557 | 36 | 44 | 23 |
| 31 Dec 15 | 481 | 39 | 37 | 23 |
| 30 Sep 15 | 416 | 39 | 31 | 22 |
| 30 Jun 15 | 351 | 40 | 25 | 21 |
| 31 Mar 15 | 333 | 39 | 25 | 21 |
| 31 Dec 14 | 315 | 39 | 25 | 21 |
| 30 Sep 14 | 329 | 46 | 32 | 21 |
| 30 Jun 14 | 343 | 54 | 38 | 22 |
| 31 Mar 14 | 359 | 54 | 41 | 22 |
| 31 Dec 13 | 375 | 54 | 44 | 23 |
양질의 수익: SFZN 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: SFZN 의 현재 순이익 이익률 (10%) 작년보다 낮습니다 (11.9%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: SFZN 의 수익은 지난 5년 동안 매년 23% 씩 크게 증가했습니다.
성장 가속화: SFZN 은(는) 지난 1년 동안 마이너스 수익 성장을 기록했기 때문에 5년 평균과 비교할 수 없습니다.
수익 대 산업: SFZN 은 지난 1년 동안 마이너스 수익 성장( -13.5% )을 기록하여 Life Sciences 업계 평균( 4.3% ).
자기자본 수익률
높은 ROE: SFZN 의 자본 수익률( 14.2% )은 낮음으로 간주됩니다.